Matt Phipps
Stock Analyst at William Blair
(0.57)
# 4,070
Out of 4,996 analysts
21
Total ratings
40%
Success rate
-27.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Initiates: Outperform | n/a | $137.03 | - | 1 | Aug 20, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Market Perform | n/a | $13.96 | - | 2 | Jul 14, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | n/a | $2.47 | - | 2 | Jul 7, 2025 | |
| CNTX Context Therapeutics | Initiates: Outperform | n/a | $0.91 | - | 1 | Apr 21, 2025 | |
| XNCR Xencor | Initiates: Outperform | n/a | $11.57 | - | 1 | Apr 21, 2025 | |
| GMAB Genmab | Upgrades: Outperform | n/a | $29.07 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $16.05 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $17.26 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $7.26 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $5.96 | - | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $44.12 | - | 1 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.65 | - | 2 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.23 | - | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.38 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $137.37 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $68.89 | - | 1 | Apr 8, 2021 |
Insmed
Aug 20, 2025
Initiates: Outperform
Price Target: n/a
Current: $137.03
Upside: -
MiNK Therapeutics
Jul 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $13.96
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.47
Upside: -
Context Therapeutics
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $0.91
Upside: -
Xencor
Apr 21, 2025
Initiates: Outperform
Price Target: n/a
Current: $11.57
Upside: -
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $29.07
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $16.05
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.26
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.26
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.96
Upside: -
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $44.12
Upside: -
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.65
Upside: -
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $23.23
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.38
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $137.37
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $68.89
Upside: -